phrykt

Oric Pharmaceuticals, Inc. (ORIC): who owns it and who trades it

As of Nov 16, 2026, ORIC insiders reported 15 open-market sales worth $2.9M and no purchases in the last 12 months, with 86% of the sale value made under pre-set 10b5-1 plans. The largest seller was Dominic Piscitelli (CFO), with $2.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Oric Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ORIC

181 funds and institutions reported ORIC shares worth $1.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Nextech Invest Ltd. with 6.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Nextech Invest Ltd.6.9%
BlackRock, Inc.6.6%
EcoR1 Capital, LLC6.5%
T. Rowe Price Associates6.4%
Viking Global Investors LP5.0%
State Street Corp4.7%
SR One Capital Management, LP4.5%
Venrock Adviser, LLC4.2%
NEA Management Company, LLC4.0%
Vanguard Capital Management LLC3.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nextech Invest Ltd.7.16M6.92%$77.6MNo change
BlackRock, Inc.6.82M6.59%$73.9M+14%
EcoR1 Capital, LLC6.73M6.50%$72.9MNo change
T. Rowe Price Associates6.62M6.39%$71.7M+23%
Viking Global Investors LP5.13M4.95%$55.5M-12%
State Street Corp4.89M4.73%$53M+32%
SR One Capital Management, LP4.62M4.46%$50M+2%
Venrock Adviser, LLC4.32M4.17%$46.8MNo change
NEA Management Company, LLC4.12M3.98%$44.6MNo change
Vanguard Capital Management LLC3.95M3.82%$42.8M+7%
AIHC Capital Management Ltd3.83M3.70%$41.5M+56%
Alkeon Capital Management LLC3.74M3.61%$40.5M-17%
Column Group LLC3.54M3.42%$38.3MNo change
Siren, L.L.C.3.00M2.90%$32.5MNo change
FMR LLC (Fidelity)2.64M2.55%$28.5M+8%
Citadel Advisors LLC2.60M2.51%$28.1M+7%
Goldman Sachs Group Inc2.45M2.37%$26.6M+66%
Geode Capital Management, LLC2.09M2.02%$22.6M+14%
First Turn Management, LLC2.02M1.95%$21.8MNo change
Orbimed Advisors LLC2.02M1.95%$21.8M-25%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ORIC insiders reported $0 of open-market purchases and $2.9M of sales. 86% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.9M
15 trades, 4 people
Sales under a 10b5-1 plan
86%
Share of sale value
Latest trade
Oct 20, 2026
Filed Oct 21, 2026

Purchases and sales by month

$1.1M$1.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 20, 2026Dominic PiscitelliCFOSale plan14,000$13.53$189KForm 4
Oct 1, 2026Richard A. HeymanDirectorSale plan3,500$12.91$45.2KForm 4
Oct 1, 2026Richard A. HeymanDirectorSale plan3,200$12.91$41.3KForm 4
Sep 28, 2026Dominic PiscitelliCFOSale plan13,400$13.53$181KForm 4
Sep 24, 2026Dominic PiscitelliCFOSale plan100$13.50$1.4KForm 4
Sep 24, 2026Dominic PiscitelliCFOSale plan500$13.51$6.8KForm 4
Aug 26, 2026Dominic PiscitelliCFOSale plan77,000$13.69$1.1MForm 4
Jul 24, 2026Richard A. HeymanDirectorSale plan7,000$12.02$84.1KForm 4
Jul 24, 2026Richard A. HeymanDirectorSale plan6,100$12.02$73.3KForm 4
Jul 6, 2026Richard A. HeymanDirectorSale plan300$12.00$3.6KForm 4
Feb 24, 2026Dominic PiscitelliCFOSale plan52,000$13.51$703KForm 4
Jan 16, 2026Richard A. HeymanDirectorSale plan3,200$12.00$38.4KForm 4
Jan 16, 2026Richard A. HeymanDirectorSale plan3,500$12.00$42KForm 4
Dec 16, 2025Pratik S MultaniChief Medical OfficerSale10,720$9.06$97.1KForm 4
Dec 16, 2025Jacob ChackoCEOSale33,374$9.06$302KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Dominic PiscitelliChief Financial Officer–$2.1MOct 20, 2026
Richard A. HeymanDirector–$328KOct 1, 2026
Jacob ChackoPRESIDENT AND CEO, Director–$302KDec 16, 2025
Pratik S MultaniChief Medical Officer–$97.1KDec 16, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ORIC short interest

High short interest. 10.4% of ORIC shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 51%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.73M ORIC shares were sold short, 10.4% of the shares outstanding, down 30.4% from the report before. At the average daily volume of 2.24M shares, buying them all back would take about 4.8 trading days (days to cover).

Shares short, % of all shares

10.4%May 15Oct 3023.0%

Days to cover

4.8May 15Oct 3019.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.73M10.35%-30%2.24M4.8
Oct 15, 202615.42M14.88%-5%1.47M10.5
Sep 30, 202616.32M15.74%-7%1.66M9.8
Sep 15, 202617.53M16.91%+2%1.23M14.2
Aug 31, 202617.27M16.66%-6%1.07M16.2
Aug 14, 202618.39M17.74%-16%1.68M11.0
Jul 31, 202621.80M21.04%-1%1.61M13.6
Jul 15, 202622.05M21.30%-0%1.63M13.5
Jun 30, 202622.11M21.36%+5%1.79M12.3
Jun 15, 202621.06M20.34%-4%2.04M10.3
May 29, 202621.94M21.19%No change1.27M17.2
May 15, 202621.94M21.20%-0%1.43M15.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Oric Pharmaceuticals company events

Oric Pharmaceuticals filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 23, 2026.

  1. Oct 23, 2026AnnouncementThe Program Update covered updated data from the Company’s Phase 1b trial of enozertinib, as well as the Company’s plans to initiate a global Phase 3 registrational trial of enozertinib in the first half of 2027: Enozertinib Phase 1b Data in 1L EGFR Atypical NSCLC Enozertinib is being evaluated in… Filing
  2. Aug 3, 2026ResultsReleased financial results. Filing
  3. Jul 30, 2026LeadershipThe Board of Directors of ORIC Pharmaceuticals, Inc. approved the ORIC Pharmaceuticals, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan (as amended, the “Inducement Plan”), in order to increase the number of shares reserved for issuance under the Inducement Plan. Filing
  4. Jun 22, 2026LeadershipORIC Pharmaceuticals, Inc. amended and restated its 2020 Equity Incentive Plan, effective as of June 18, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below). Filing
  5. May 4, 2026ResultsReleased financial results. Filing
  6. Mar 31, 2026AnnouncementORIC Pharmaceuticals, Inc. presented a rinzimetostat (ORIC-944) program update on March 31, 2026. Filing
  7. Feb 23, 2026AnnouncementORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement SM with Jefferies LLC to sell shares of the Company’s common stock, par value $0.0001 per share, from time to time, through an “at the market offering” program under which Jefferies acts as sales agent. Filing
  8. Feb 23, 2026ResultsReleased financial results. Filing
  9. Dec 8, 2025AnnouncementORIC Pharmaceuticals, Inc. presented an enozertinib (ORIC-114) program update on December 6, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Oric Pharmaceuticals financials

Famous investors that hold ORIC

4 of the 50 well-known investors we track reported holding ORIC in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $48M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20263.56M$48M0.1%-31%
Ken Griffin · Citadel AdvisorsQ3 20262.11M$28.4M0.0%-19%
Israel Englander · Millennium ManagementQ3 2026713,325$9.6M0.0%+2%
Paul Tudor Jones · Tudor Investment CorpQ3 2026108,852$1.5M0.0%+157%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ORIC in the last 120 days.

FiledHolderFormStake
Nov 16, 2026EcoR1 Capital, LLC13G/A2.9%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.9%
Nov 16, 2026VIKING GLOBAL INVESTORS LP13G/A5.7%
Nov 16, 2026EcoR1 Capital, LLC13G/A2.9%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.9%
Nov 16, 2026VIKING GLOBAL INVESTORS LP13G/A5.7%

Questions about Oric Pharmaceuticals, Inc. (ORIC) stock

Who owns the most ORIC stock?

The largest reported owner of Oric Pharmaceuticals, Inc. (ORIC) is Nextech Invest Ltd., with 6.9% of the company. In total, 181 funds and institutions reported holding ORIC at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ORIC insiders buying or selling?

In the last 12 months, ORIC insiders reported no open-market purchases and 15 sales worth $2.9M. The latest trade was on Oct 20, 2026. See every trade.

What is the short interest in ORIC?

As of Oct 30, 2026, 10.73M ORIC shares were sold short, 10.4% of the shares outstanding, down 30.4% from the report before. At the average daily volume of 2.24M shares, buying them all back would take about 4.8 trading days (days to cover). See the history.

Which famous investors hold ORIC?

4 of the 50 well-known investors we track reported ORIC in their latest 13F filing, including Andreas Halvorsen, Ken Griffin, Israel Englander. The largest position is worth $48M. See all holders.

Executive pay

Oric Pharmaceuticals's chief executive was paid a total of $5.6M for the year ended Dec 31, 2025, up 5% from $5.3M the year before. In the last 12 months, Oric Pharmaceuticals's executives and directors bought no stock on the open market and sold $2.9M.

Chief executive, total pay$5.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$5.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.